Skip to main content

JAK/TYK2

      Rheumatology Roundup
      Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23. This included the following abstracts: 0025 Cannibinoids & pain 1584 TMP/SMX in GPA 0607 CAR-T cells in…
      We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to ACR Convergence 2023 there has been relatively little to say about…
      JAKi, especially BARI, may be useful and safe in controlling both pulmonary and joint disease in RA-ILD patients, even i
      8 months ago
      JAKi, especially BARI, may be useful and safe in controlling both pulmonary and joint disease in RA-ILD patients, even in refractory cases. Evolution of FVC and DLCO remained stable in first 12 months. Serrano-Combarro A, Abst#2174 #ACR23 @RheumNow https://t.co/82mMn5oh15 https://t.co/e7wrgmTOTA
      Serrano-Combarro et al. JAKi in RA-ILD. 73 patients on JAKi (74% Bari). Many had prev received abatacept/rituximab. HRCT
      8 months ago
      Serrano-Combarro et al. JAKi in RA-ILD. 73 patients on JAKi (74% Bari). Many had prev received abatacept/rituximab. HRCT improved/stable in 76%. Dyspnoea stable/improved in 95%. Abstr#2174 #ACR23 @RheumNow https://t.co/j6SiEzSRif
      Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was
      8 months ago
      Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was withdrawn in 50 patients (21.5%) (ILD worsening 20, joint worsening 15, serious infections 7, others 8) Abstr#2165 #ACR23 @RheumNow https://t.co/SinE4GgFRE https://t.co/M1Nnce58OE
      Who gives a ‘JAK’ why and how they work, as long as they do!

      Several abstracts have studied the mechanism of actio
      8 months ago
      Who gives a ‘JAK’ why and how they work, as long as they do! Several abstracts have studied the mechanism of action of JAKi in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. #ACR23 https://t.co/xqQF8SULgp https://t.co/DZtEly8GEq
      Daily Recap - TUESDAY